Effects Of Metformin And Myo-Inositol In Combination Versus Metformin As Monotherapy On The Metabolic Profile Of Polycystic Ovarian Syndrome Patients With Infertility

Abstract

Objective: To compare the effects of myo-inositol combined with metformin vs. metformin used alone on the metabolic profile of patients with polycystic ovarian syndrome with infertility.

Methods: A randomised controlled trial that was double-blinded was conducted from September 2022 to February 2023. One hundred fourteen PCOS females with infertility were randomly assigned to 57 people made up Group A, which received oral Metformin in a dose of 500 mg 3 times per day together with oral Myo-inositol 4 g once per day; 57 people made up Group B, which received oral Metformin in a dose of 500 mg 3 times per day only. Following the start of medication, all hormonal and metabolic profile parameters were assessed at baseline, one, three and, six months later. Our main goal was to improve polycystic ovarian syndrome patients' metabolic profiles regarding mean change in serum Triglycerides, serum HDL and mean HOMA-IR index throughout one, three and six months. Comparable demographic, hormonal, and biochemical baseline characteristics were present in both groups.

Results: In comparison to Group B, Group A's mean serum triglycerides improved (p=0.16) although not significant, significant improvement in mean serum HDL in Group A as compared to Group B (p=0.00), additionally a significant improvement in the mean HOMA-IR index in Group A when compared to Group B was observed.

Conclusion: Compared to Metformin administered as a monotherapy, it seems promising to treat PCOS and insulin resistance using a combination of metformin and myo-inositol.